Nanoparticle-enhanced mesalazine therapy for inflammatory bowel disease

SUTARIA, RAJVANSHI; Mok, Zi Hong

doi:10.1016/j.pscia.2023.100014

Journal article 311 views 96 downloads

Nanoparticle-enhanced mesalazine therapy for inflammatory bowel disease

RAJVANSHI SUTARIA, Zi Hong Mok

Pharmaceutical Science Advances, Volume: 1, Issue: 2, Start page: 100014

Swansea University Authors: RAJVANSHI SUTARIA, Zi Hong Mok

PDF | Version of Record

This is an open access article under the CC BY-NC-ND license.
Download (1.91MB)

Check full text

DOI (Published version): 10.1016/j.pscia.2023.100014

Abstract

Inflammatory bowel disease (IBD) is a chronic inflammatory illness that causes ongoing bodily inflammation in the gastrointestinal tract. Drug-targeted delivery of aminosalicylates such as mesalazine at the inflammation sites, to treat ulcerative colitis (UC) and Crohn's disease (CD) has remain...

Full description

Published in:	Pharmaceutical Science Advances
ISSN:	2773-2169
Published:	Elsevier BV 2023
Online Access:	Check full text
URI:	https://cronfa.swan.ac.uk/Record/cronfa65723

first_indexed	2024-03-01T14:54:30Z
last_indexed	2024-11-25T14:16:42Z
id	cronfa65723
recordtype	SURis
fullrecord	<?xml version="1.0"?><rfc1807><datestamp>2024-04-25T22:15:28.9618635</datestamp><bib-version>v2</bib-version><id>65723</id><entry>2024-03-01</entry><title>Nanoparticle-enhanced mesalazine therapy for inflammatory bowel disease</title><swanseaauthors><author><sid>818a65dfaa99c231cb67f61d753df7b4</sid><firstname>RAJVANSHI</firstname><surname>SUTARIA</surname><name>RAJVANSHI SUTARIA</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>4a0b8a58c748d6a2c87a54f263f4d397</sid><ORCID>0000-0002-1231-5048</ORCID><firstname>Zi Hong</firstname><surname>Mok</surname><name>Zi Hong Mok</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2024-03-01</date><abstract>Inflammatory bowel disease (IBD) is a chronic inflammatory illness that causes ongoing bodily inflammation in the gastrointestinal tract. Drug-targeted delivery of aminosalicylates such as mesalazine at the inflammation sites, to treat ulcerative colitis (UC) and Crohn's disease (CD) has remained a difficulty. Current mesalazine formulations, including tablets, suppositories, and enemas, are typically associated with adverse systemic effects. The use of nanocarriers however has opened the possibility of improved local targeting and pharmacokinetics of loaded mesalazine, based on the new physicochemical properties of the drug vehicle. The innovative nanoencapsulation of mesalazine has demonstrated success in targeting inflammatory regions and treating mild to moderate IBD. The use of nanocarriers, such as lipid-based, polymeric, and inorganic nanocarriers, has demonstrated improved overall solubility, absorption, and bioavailability of mesalazine while minimising the side effects associated with their absorption. This review aims to offer an insight into what is currently known about IBD, and the nanotechnological approaches for the improvement of mesalazine therapy for IBD.</abstract><type>Journal Article</type><journal>Pharmaceutical Science Advances</journal><volume>1</volume><journalNumber>2</journalNumber><paginationStart>100014</paginationStart><paginationEnd/><publisher>Elsevier BV</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint>2773-2169</issnPrint><issnElectronic/><keywords>Inflammatory bowel disease; Ulcerative colitis; Crohn&apos;s disease; Mesalazine; Nanocarriers</keywords><publishedDay>1</publishedDay><publishedMonth>12</publishedMonth><publishedYear>2023</publishedYear><publishedDate>2023-12-01</publishedDate><doi>10.1016/j.pscia.2023.100014</doi><url/><notes/><college>COLLEGE NANME</college><CollegeCode>COLLEGE CODE</CollegeCode><institution>Swansea University</institution><apcterm>Another institution paid the OA fee</apcterm><funders>Shandong University</funders><projectreference/><lastEdited>2024-04-25T22:15:28.9618635</lastEdited><Created>2024-03-01T14:50:03.4001951</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Pharmacy</level></path><authors><author><firstname>RAJVANSHI</firstname><surname>SUTARIA</surname><order>1</order></author><author><firstname>Zi Hong</firstname><surname>Mok</surname><orcid>0000-0002-1231-5048</orcid><order>2</order></author></authors><documents><document><filename>65723__29626__cb5b92282fbc4be0acd732382665e8d5.pdf</filename><originalFilename>65723.pdf</originalFilename><uploaded>2024-03-05T09:12:56.0500459</uploaded><type>Output</type><contentLength>1999186</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>This is an open access article under the CC BY-NC-ND license.</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>http://creativecommons.org/licenses/by-nc- nd/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling	2024-04-25T22:15:28.9618635 v2 65723 2024-03-01 Nanoparticle-enhanced mesalazine therapy for inflammatory bowel disease 818a65dfaa99c231cb67f61d753df7b4 RAJVANSHI SUTARIA RAJVANSHI SUTARIA true false 4a0b8a58c748d6a2c87a54f263f4d397 0000-0002-1231-5048 Zi Hong Mok Zi Hong Mok true false 2024-03-01 Inflammatory bowel disease (IBD) is a chronic inflammatory illness that causes ongoing bodily inflammation in the gastrointestinal tract. Drug-targeted delivery of aminosalicylates such as mesalazine at the inflammation sites, to treat ulcerative colitis (UC) and Crohn's disease (CD) has remained a difficulty. Current mesalazine formulations, including tablets, suppositories, and enemas, are typically associated with adverse systemic effects. The use of nanocarriers however has opened the possibility of improved local targeting and pharmacokinetics of loaded mesalazine, based on the new physicochemical properties of the drug vehicle. The innovative nanoencapsulation of mesalazine has demonstrated success in targeting inflammatory regions and treating mild to moderate IBD. The use of nanocarriers, such as lipid-based, polymeric, and inorganic nanocarriers, has demonstrated improved overall solubility, absorption, and bioavailability of mesalazine while minimising the side effects associated with their absorption. This review aims to offer an insight into what is currently known about IBD, and the nanotechnological approaches for the improvement of mesalazine therapy for IBD. Journal Article Pharmaceutical Science Advances 1 2 100014 Elsevier BV 2773-2169 Inflammatory bowel disease; Ulcerative colitis; Crohn's disease; Mesalazine; Nanocarriers 1 12 2023 2023-12-01 10.1016/j.pscia.2023.100014 COLLEGE NANME COLLEGE CODE Swansea University Another institution paid the OA fee Shandong University 2024-04-25T22:15:28.9618635 2024-03-01T14:50:03.4001951 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Pharmacy RAJVANSHI SUTARIA 1 Zi Hong Mok 0000-0002-1231-5048 2 65723__29626__cb5b92282fbc4be0acd732382665e8d5.pdf 65723.pdf 2024-03-05T09:12:56.0500459 Output 1999186 application/pdf Version of Record true This is an open access article under the CC BY-NC-ND license. true eng http://creativecommons.org/licenses/by-nc- nd/4.0/
title	Nanoparticle-enhanced mesalazine therapy for inflammatory bowel disease
spellingShingle	Nanoparticle-enhanced mesalazine therapy for inflammatory bowel disease RAJVANSHI SUTARIA Zi Hong Mok
title_short	Nanoparticle-enhanced mesalazine therapy for inflammatory bowel disease
title_full	Nanoparticle-enhanced mesalazine therapy for inflammatory bowel disease
title_fullStr	Nanoparticle-enhanced mesalazine therapy for inflammatory bowel disease
title_full_unstemmed	Nanoparticle-enhanced mesalazine therapy for inflammatory bowel disease
title_sort	Nanoparticle-enhanced mesalazine therapy for inflammatory bowel disease
author_id_str_mv	818a65dfaa99c231cb67f61d753df7b4 4a0b8a58c748d6a2c87a54f263f4d397
author_id_fullname_str_mv	818a65dfaa99c231cb67f61d753df7b4_*_RAJVANSHI SUTARIA 4a0b8a58c748d6a2c87a54f263f4d397_*_Zi Hong Mok
author	RAJVANSHI SUTARIA Zi Hong Mok
author2	RAJVANSHI SUTARIA Zi Hong Mok
format	Journal article
container_title	Pharmaceutical Science Advances
container_volume	1
container_issue	2
container_start_page	100014
publishDate	2023
institution	Swansea University
issn	2773-2169
doi_str_mv	10.1016/j.pscia.2023.100014
publisher	Elsevier BV
college_str	Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id	facultyofmedicinehealthandlifesciences
hierarchy_top_title	Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id	facultyofmedicinehealthandlifesciences
hierarchy_parent_title	Faculty of Medicine, Health and Life Sciences
department_str	Swansea University Medical School - Pharmacy{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Pharmacy
document_store_str	1
active_str	0
description	Inflammatory bowel disease (IBD) is a chronic inflammatory illness that causes ongoing bodily inflammation in the gastrointestinal tract. Drug-targeted delivery of aminosalicylates such as mesalazine at the inflammation sites, to treat ulcerative colitis (UC) and Crohn's disease (CD) has remained a difficulty. Current mesalazine formulations, including tablets, suppositories, and enemas, are typically associated with adverse systemic effects. The use of nanocarriers however has opened the possibility of improved local targeting and pharmacokinetics of loaded mesalazine, based on the new physicochemical properties of the drug vehicle. The innovative nanoencapsulation of mesalazine has demonstrated success in targeting inflammatory regions and treating mild to moderate IBD. The use of nanocarriers, such as lipid-based, polymeric, and inorganic nanocarriers, has demonstrated improved overall solubility, absorption, and bioavailability of mesalazine while minimising the side effects associated with their absorption. This review aims to offer an insight into what is currently known about IBD, and the nanotechnological approaches for the improvement of mesalazine therapy for IBD.
published_date	2023-12-01T20:28:46Z
_version_	1821348123228766208
score	11.04748

Nanoparticle-enhanced mesalazine therapy for inflammatory bowel disease

Similar Items